Should I Buy MAIA? MAIA 2026 Analysis

Should You Buy Maia Biotechnology Inc (MAIA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.970

1 Day change

3.14%

52 Week Range

3.190

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price action is bearish and breaking into/through near-term support while momentum (MACD) worsens.
No Intellectia buy signals (AI Stock Picker / SwingMax), so there is no edge suggesting an immediate, impatient entry.
News flow provided is not MAIA-specific and does not introduce a clear near-term catalyst to reverse the downtrend.
With the stock sitting below/near S1 (~1.983) and next support at ~1.673, risk/reward favors waiting (or avoiding) rather than buying immediately.

Technical Analysis

Trend/Momentum: Bearish. MACD histogram is negative (-0.0657) and expanding lower, indicating strengthening downside momentum.
RSI: RSI(6) ~39.4 (weak/soft). Not oversold enough to imply a high-conviction bounce, but confirms bearish pressure.
Moving averages: Converging MAs suggests indecision, but current momentum and price drop tilt bearish.
Key levels: Pivot 2.483 (well above current price 1.95 = below pivot = bearish). Support S1 1.983 (price ~1.95 is slightly below/at this level), next S2 1.673. Resistance R1 2.983.
Pattern-based forward odds: Similar-pattern expectation is slightly negative over 1 week (-0.67%) and 1 month (-1.22%), offering no statistical tailwind.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Broad oncology market tailwinds mentioned in news (industry-level), but no MAIA-specific catalyst was provided.
- Loss metrics improved YoY in the latest reported quarter (reduced losses vs prior year), which can support sentiment if sustained.

Neutral/Negative Catalysts

- Strong near-term bearish momentum (expanding negative MACD) alongside a sharp daily drop (~-7.94%) indicates active selling pressure.
- Price is trading below the pivot and slipping under/around S1 support (~~1.983), raising the probability of a move toward S2 (~~1.673).
- News items provided focus on another company (Oncolytics) rather than MAIA, implying limited event-driven support for MAIA right now.
- Trading trends: Hedge funds neutral and insiders neutral—no supportive accumulation signal.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: 0 (no reported revenue; no YoY improvement).
Net income: -8.90M (improved vs prior year; data indicates +225.41% YoY improvement, i.e., losses narrowed).
EPS: -0.27 (improved YoY by 145.45%, i.e., less negative).
Takeaway: Financials show reduced losses but still pre-revenue; fundamentals do not supply a near-term “must-buy-now” trigger.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating / price target change data was provided, so no clear Wall Street consensus trend can be confirmed.
Practical read-through: absence of visible upgrades/targets in the provided data means sentiment support from analysts cannot be relied upon for an immediate buy decision.
Politicians/Congress: No recent congress trading data available (no influential buying/selling signal to lean on).

1 Analyst Rating

Wall Street analysts forecast MAIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAIA is 14 USD with a low forecast of 14 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.910

Low

Averages

High